EPISODE · Mar 12, 2025 · 9 MIN
28: Novo Nordisk's Bold Leap into Rare Diseases
Novo Nordisk is strategically expanding into rare diseases, shifting from its traditional focus on common chronic conditions, by significantly increasing R&D investment and executing key acquisitions to build a strong portfolio in blood, endocrine, and hemato-renal disorders. The company aims to achieve long-term leadership in this space through internal innovation, strategic partnerships, and further mergers and acquisitions. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
28: Novo Nordisk's Bold Leap into Rare Diseases
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m